Zimmer Biomet (ZBH) Expected to Announce Earnings on Monday

Zimmer Biomet (NYSE:ZBH - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of $1.77 per share and revenue of $1.89 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 8.150-8.350 EPS.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business earned $2.20 EPS. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

NYSE ZBH traded down $0.95 on Thursday, reaching $102.10. The company's stock had a trading volume of 630,750 shares, compared to its average volume of 1,663,091. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $105.72 and a 200 day moving average price of $106.55. The firm has a market cap of $20.20 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. Zimmer Biomet has a 52 week low of $93.10 and a 52 week high of $123.96.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. Zimmer Biomet's payout ratio is presently 21.57%.

Analysts Set New Price Targets

ZBH has been the subject of several research analyst reports. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $124.15.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

An institutional investor recently bought a new position in Zimmer Biomet stock. Brighton Jones LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,936 shares of the medical equipment provider's stock, valued at approximately $204,000. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.